avatrombopag is an approved drug (FDA (2018), EMA (2019))
Compound class:
Synthetic organic
Comment: Avatrombopag is a second generation, small molecule, orally administered thrombopoietin receptor agonist [1]. It was discovered through its ability to mimic the action of endogenous thrombopoietin which is the primary physiological regulator of normal platelet production. The pharmacokinetics, pharmacodynamics, pharmacogenomics, safety, and tolerability of avatrombopag were reported by Nomoto et al. in 2017 [2].
|
|
Classification | |
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2018), EMA (2019)) |
IUPAC Name |
1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid |
International Nonproprietary Names | |
INN number | INN |
9571 | avatrombopag |
Synonyms | |
AKR-501 [1] | Doptelet® | E5501 [4] | YM477 |
Database Links | |
ChEMBL Ligand | CHEMBL2103883 |
DrugBank Ligand | DB11995 |
DrugCentral Ligand | 5285 |
GtoPdb PubChem SID | 374883840 |
PubChem CID | 9852519 |
Search Google for chemical match using the InChIKey | OFZJKCQENFPZBH-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | OFZJKCQENFPZBH |
Search PubMed clinical trials | avatrombopag |
Search PubMed titles | avatrombopag |
Search PubMed titles/abstracts | avatrombopag |
UniChem Compound Search for chemical match using the InChIKey | OFZJKCQENFPZBH-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | OFZJKCQENFPZBH-UHFFFAOYSA-N |